2450 HOLCOMBE BLVD, HOUSTON, TX
Material disclosure
Announces 1-for-12 Reverse Stock Split
Stockholders Approve 2026 Equity Incentive Plan at Special Meeting
Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Salarius Pharmaceuticals Re-Elects Directors at 2025 Annual Meeting
Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Executive Appointments - Frederick E. Pierce Named CEO, Barbara Hibner CSO
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Free Writing Prospectus
Correspondence
Submission Upload